文献速递肾小球疾病

原发性IgA肾病的新型治疗范式

Novel Treatment Paradigms: Primary IgA Nephropathy.
PubMed 文献 · Kidney Int Rep · 2023-12-01

IgA肾病是最常见的原发性肾小球肾炎,约30%至45%的患者在诊断后20至25年内进展至肾衰竭。本文综述了当前、近期获批及新兴的IgA肾病治疗,包括靶向释放布地奈德和sparsentan等。

要点

  • 约30%至45%的IgA肾病患者在20至25年内进展至肾衰竭。
  • 蛋白尿减少作为替代终点获监管接受,加速了新药审批。
  • 靶向释放布地奈德和sparsentan已基于此途径获批。

核心结论

  • IgA肾病治疗格局正快速演变,多种靶向病理生理通路的疗法正在开发或已获批。

研究设计与样本

  • 本文为综述,未报告系统检索范围。

主要发现

  • 约30%至45%的IgA肾病患者在诊断后20至25年内进展至肾衰竭。
  • 靶向释放布地奈德和sparsentan已基于蛋白尿减少替代终点获批。
  • 黏膜免疫系统、B细胞、补体系统和内皮素系统等病理生理见解推动了疗法开发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Approximately 30% to 45% of patients progress to kidney failure (KF) within 20 to 25 years of diagnosis, and there has long been a lack of effective treatments. The therapeutic landscape in IgAN is rapidly evolving, driven in large part by the acceptance of the surrogate clinical trial end point of proteinuria reduction by regulatory authorities for the accelerated approval of new therapies. Two drugs, targeted release formulation (TRF)-budesonide (nefecon) and sparsentan, have recently been approved under this scheme. Advancing insights into the pathophysiology of IgAN, including the roles of the mucosal immune system, B-cells, the complement system, and the endothelin system have driven development of therapies that target these factors. This review outlines current, recently approved, and emerging therapies for IgAN.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Selvaskandan H, Barratt J, Cheung CK, et al. Novel Treatment Paradigms: Primary IgA Nephropathy. Kidney Int Rep. 2023. PMID: 38344739. doi:10.1016/j.ekir.2023.11.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。